Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer

被引：4
|
作者：
Tombal, Bertrand
Borre, Michael
Rathenborg, Per
Werbrouck, Patrick
Heidenreich, Axel
Iversen, Peter
Baskin-Bey, Edwina S.
Perabo, Frank
Phung, De
Smith, Matthew Raymond
机构：
[1] Catholic Univ Louvain, Clin Univ St Luc, B-1200 Brussels, Belgium
[2] Arhus Univ Hosp, Dept Urol, Skejby, Denmark
[3] Herlev Hosp, DK-2730 Herlev, Denmark
[4] AZ Groeninge Kortrijk, Kortrijk, Belgium
[5] Klin & Poliklin Urol, North Rhine Westphalia, Germany
[6] Univ Copenhagen, Rigshosp, DK-2100 Copenhagen, Denmark
[7] Astellas Pharma Europe Ltd, Staines, England
[8] Astellas Pharma Inc, Leiderdorp, Netherlands
[9] Astellas Pharma Europe BV, Leiderdorp, Netherlands
[10] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 06期
关键词：
D O I：
10.1200/jco.2013.31.6_suppl.18
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
18
引用
收藏
页数：1
相关论文
共 50 条
  • [21] A randomized, phase II study of ATN-224 in patients with biochemically relapsed, hormone-naive prostate cancer: A DOD/PCF Prostate Cancer Clinical Trials Consortium trial
    Lin, J.
    Beer, T. M.
    Ryan, C. J.
    Mathew, P.
    Wilding, G.
    Morris, M.
    Callahan, J. A.
    Gordon, G.
    Reich, S.
    Carducci, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [22] Genomic profiling of hormone-naive lymph node metastases in patients with prostate cancer
    Paris, Pamela L.
    Hofer, Matthias D.
    Albo, Giancarlo
    Kuefer, Rainer
    Gschwend, Juergen E.
    Hautmann, Richard E.
    Fridyland, Jane
    Simko, Jeffrey
    Carroll, Peter R.
    Rubin, Mark A.
    Collins, Colin
    NEOPLASIA, 2006, 8 (12): : 1083 - U54
  • [23] A phase Ib trial of mushroom powder in biochemically recurrent, hormone-naive prostate cancer
    Twardowski, Przemyslaw
    Frankel, Paul Henry
    Pal, Sumanta Kumar
    Synold, Timothy W.
    Ruel, Christopher
    Junqueira, Maribel
    Tina Nguyen
    Palomares, Melanie R.
    Tryon, Pamela Renee
    Chen, Shiuan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [24] Phase II study of enzalutamide monotherapy with radiation therapy for intermediate risk prostate cancer.
    Bubley, Glenn
    Kaplan, Irving D.
    Werner, Lillian
    Bhatt, Rupal Satish
    Taplin, Mary Ellen
    Mahoney, Kathleen Margaret
    Nguyen, Paul
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [25] 13-cis retinoic acid and complete androgen blockade in advanced hormone-naive prostate cancer patients:: Report of a phase II randomized study
    Ferrari, AC
    Stone, N
    Stock, R
    Bednar, M
    Esseesse, I
    Singh, H
    Baldwin, Y
    Mandeli, J
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) : 538 - 544
  • [26] A phase II, open-label, single-arm, efficacy, and safety study of MDV3100 in patients with hormone-naive prostate cancer
    Baskin-Bey, E. S.
    Holtkamp, G. M.
    Smith, M. R.
    Ouatas, T.
    Phung, D.
    Tombal, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [27] Phase II Clinical Trial of GM-CSF Treatment in Patients with Hormone-Refractory or Hormone-Naive Adenocarcinoma of the Prostate
    Amato, Robert J.
    Hernandez-McClain, Joan
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2008, 2 : 471 - 475
  • [28] Circulating tumor cell in hormone-naive metastatic prostate cancer
    Kanayama, M.
    Nagaya, N.
    Nagata, M.
    Horie, S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Medical treatment of patients with hormone-naive metastatic prostate cancer: what's new?
    Cathomas, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 192 - 192
  • [30] Fatigue in hormone-naive prostate cancer patients treated with radical prostatectomy or definitive radiotherapy
    Kyrdalen, A. E.
    Dahl, A. A.
    Hernes, E.
    Cvancarova, M.
    Fossa, S. D.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2010, 13 (02) : 144 - 150
12345